BACKGROUND: Normal(ization) of serum carbohydrate 19-9 (CA19-9) before/after surgery has not been compared in patients with pancreatic adenocarcinoma (PDAC) treated with neoadjuvant therapy (NT) versus surgery-first (SF). METHODS: Characteristics for patients with PDAC who underwent resection from July 2011 to October 2018 were collected. Patients with pre-/postoperative CA19-9, bilirubin <2 mg/dL, and initial CA19-9 > 1 U/ml were included. Overall survival (OS) and recurrence-free survival (RFS) were compared by pre-/postoperative CA19-9. RESULTS: In patients receiving NT, normal pre/postoperative CA19-9 ("NTnl/nl ") was associated with median RFS and OS (26 and 77mo), followed by those who normalized after surgery ("NTabnl/nl " 16 and 44mo). For SF patients, normal pre-/postoperative CA19-9 ("SFnl/nl ") was associated with median RFS and OS (115 and not estimable mo), followed by those who normalized after resection ("SFabnl/nl " 18 and 49mo). Groups "NTabnl/abnl " and "SFabnl/abnl " with elevated CA19-9 both before and after resection had the worst median RFS and OS durations. CONCLUSIONS: While a normal(ized) postoperative CA19-9 may result in similar survival as preoperative normal(ization), postoperative normalization failed to occur in nearly 30% of SF patients. NT should be considered in patients presenting with elevated CA19-9. If considering SF, ideal patients may include those with normal CA19-9 at presentation.
BACKGROUND: Normal(ization) of serum carbohydrate 19-9 (CA19-9) before/after surgery has not been compared in patients with pancreatic adenocarcinoma (PDAC) treated with neoadjuvant therapy (NT) versus surgery-first (SF). METHODS: Characteristics for patients with PDAC who underwent resection from July 2011 to October 2018 were collected. Patients with pre-/postoperative CA19-9, bilirubin <2 mg/dL, and initial CA19-9 > 1 U/ml were included. Overall survival (OS) and recurrence-free survival (RFS) were compared by pre-/postoperative CA19-9. RESULTS: In patients receiving NT, normal pre/postoperative CA19-9 ("NTnl/nl ") was associated with median RFS and OS (26 and 77mo), followed by those who normalized after surgery ("NTabnl/nl " 16 and 44mo). For SF patients, normal pre-/postoperative CA19-9 ("SFnl/nl ") was associated with median RFS and OS (115 and not estimable mo), followed by those who normalized after resection ("SFabnl/nl " 18 and 49mo). Groups "NTabnl/abnl " and "SFabnl/abnl " with elevated CA19-9 both before and after resection had the worst median RFS and OS durations. CONCLUSIONS: While a normal(ized) postoperative CA19-9 may result in similar survival as preoperative normal(ization), postoperative normalization failed to occur in nearly 30% of SF patients. NT should be considered in patients presenting with elevated CA19-9. If considering SF, ideal patients may include those with normal CA19-9 at presentation.
Authors: Joshua G Barton; John P Bois; Michael G Sarr; Christina M Wood; Rui Qin; Kristine M Thomsen; Michael L Kendrick; Michael B Farnell Journal: J Gastrointest Surg Date: 2009-09-09 Impact factor: 3.452
Authors: Margaret A Tempero; Mokenge P Malafa; Mahmoud Al-Hawary; Stephen W Behrman; Al B Benson; Dana B Cardin; E Gabriela Chiorean; Vincent Chung; Brian Czito; Marco Del Chiaro; Mary Dillhoff; Timothy R Donahue; Efrat Dotan; Cristina R Ferrone; Christos Fountzilas; Jeffrey Hardacre; William G Hawkins; Kelsey Klute; Andrew H Ko; John W Kunstman; Noelle LoConte; Andrew M Lowy; Cassadie Moravek; Eric K Nakakura; Amol K Narang; Jorge Obando; Patricio M Polanco; Sushanth Reddy; Marsha Reyngold; Courtney Scaife; Jeanne Shen; Charles Vollmer; Robert A Wolff; Brian M Wolpin; Beth Lynn; Giby V George Journal: J Natl Compr Canc Netw Date: 2021-04-01 Impact factor: 11.908
Authors: Ching-Wei D Tzeng; Hop S Tran Cao; Jeffrey E Lee; Peter W T Pisters; Gauri R Varadhachary; Robert A Wolff; James L Abbruzzese; Christopher H Crane; Douglas B Evans; Huamin Wang; Daniel E Abbott; Jean-Nicolas Vauthey; Thomas A Aloia; Jason B Fleming; Matthew H G Katz Journal: J Gastrointest Surg Date: 2013-11-16 Impact factor: 3.452
Authors: Susan Tsai; Ben George; David Wittmann; Paul S Ritch; Ashley N Krepline; Mohammed Aldakkak; Chad A Barnes; Kathleen K Christians; Kulwinder Dua; Michael Griffin; Catherine Hagen; William A Hall; Beth A Erickson; Douglas B Evans Journal: Ann Surg Date: 2020-04 Impact factor: 12.969
Authors: E Versteijne; J A Vogel; M G Besselink; O R C Busch; J W Wilmink; J G Daams; C H J van Eijck; B Groot Koerkamp; C R N Rasch; G van Tienhoven Journal: Br J Surg Date: 2018-04-30 Impact factor: 6.939